NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders

Recruiting

Conditions: Tonsil Disorder
Sleep Disordered Breathing
Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa)
Obstructive Sleep Apnea
Tonsillitis

First Posted Date: 2022-12-19

Last Posted Date: 2024-11-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1500

Registration Number: NCT05656365

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

A Repository to Study Host-Microbiome Interactions in Health and Disease

Recruiting

Conditions: Pregnancy
Inflammatory Diseases
Healthy Controls
Pediatric Illnesses

First Posted Date: 2022-12-19

Last Posted Date: 2024-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 600

Registration Number: NCT05656378

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers

Phase 2

Recruiting

Conditions: Healthy Volunteer
Weight Gain
Metabolic Effects
Integrase Strand Transfer Inhibitors

Interventions: Drug: Tenofovir alafenamide
Drug: Dolutegravir

First Posted Date: 2022-12-15

Last Posted Date: 2025-01-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT05652478

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)

Phase 1

Suspended

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Drug: Normal Saline
Other: PfSPZ Diluent

First Posted Date: 2022-12-15

Last Posted Date: 2025-01-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 400

Registration Number: NCT05652504

Locations: 🇲🇱
Ou(SqrRoot)(Copyright)less(SqrRoot)(Copyright)bougou, Health Research Center, Ou(SqrRoot)(Copyright)less(SqrRoot)(Copyright)bougou, Mali

The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel Disease

Withdrawn

Conditions: Ulcerative Colitis
Inflammatory Bowel Disease
Crohn's Disease

First Posted Date: 2022-12-15

Last Posted Date: 2023-06-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT05652491

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
🇺🇸
Inova Fairfax Medical Campus, Falls Church, Virginia, United States

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

Phase 1

Completed

Conditions: Bacterial Infection

Interventions: Drug: Ertapenem
Other: Placebo
Drug: WCK 6777
Drug: Zidebactam

First Posted Date: 2022-12-09

Last Posted Date: 2024-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 54

Registration Number: NCT05645757

Locations: 🇺🇸
Altasciences Inc - Kansas City, Overland Park, Kansas, United States

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

Phase 2

Recruiting

Conditions: HIV-associated Tuberculosis

Interventions: Drug: Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC
Drug: DTG 50 mg orally QD plus TDF/3TC
Drug: 2HPZM
Drug: 2HPM

First Posted Date: 2022-11-30

Last Posted Date: 2024-08-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT05630872

Locations: 🇿🇦
University of Cape Town Lung Institute (UCTLI) CRS (Site # 31792), Mowbray, Cape Town, Western Cape, South Africa
🇿🇦
Durban International CRS (Site # 11201), Westridge, Durban RSA, South Africa
🇿🇦
South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site # 31793), Worcester, Western Province, South Africa

and more 1 locations

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Phase 2

Completed

Conditions: HIV-1-infection

Interventions: Drug: CVC 150 mg
Other: Placebo for CVC 150 mg
Other: Placebo for CVC 300 mg
Drug: CVC 300 mg

First Posted Date: 2022-11-30

Last Posted Date: 2024-07-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 110

Registration Number: NCT05630885

Locations: 🇺🇸
Weill Cornell Chelsea CRS (Site # 7804), New York, New York, United States
🇺🇸
Chapel Hill CRS (Site # 3201), Chapel Hill, North Carolina, United States
🇺🇸
Washington University Therapeutics (WT) CRS (Site # 2101), Saint Louis, Missouri, United States

and more 16 locations

A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults

Phase 1

Active, not recruiting

Conditions: HIV

Interventions: Biological: VRC-HIVMAB0115-00-AB

First Posted Date: 2022-11-25

Last Posted Date: 2024-04-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT05627258

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

Phase 1

Recruiting

Conditions: HIV-1

Interventions: Other: Sterile Saline
Biological: 3BNC117-LS
Biological: 10-1074-LS

First Posted Date: 2022-11-10

Last Posted Date: 2024-11-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT05612178

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy